tiprankstipranks
Advertisement
Advertisement

CANbridge Reshuffles Key Company Secretary and Compliance Roles After Resignation

Story Highlights
  • CANbridge’s joint company secretary and Hong Kong process agent, Mr. Wong, resigned effective March 30, 2026.
  • The company reassigned compliance roles to Ms. Ma and Ms. Lin, maintaining continuity in Hong Kong regulatory obligations.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CANbridge Reshuffles Key Company Secretary and Compliance Roles After Resignation

Claim 55% Off TipRanks

An update from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available.

CANbridge Pharmaceuticals announced that joint company secretary, authorised representative and Hong Kong process agent, Mr. Wai Chiu Wong, has resigned from all his roles with effect from March 30, 2026, citing no disagreement with the board or issues requiring shareholder attention. The move triggers a reshuffling of compliance responsibilities, with existing joint company secretary Ms. Qian Ma continuing as company secretary and being appointed as authorised representative, while Ms. Lin Sio Ngo assumes the role of process agent, ensuring continuity in the company’s regulatory and procedural obligations in Hong Kong.

The board expressed gratitude to Mr. Wong for his contributions and welcomed Ms. Ma and Ms. Lin in their expanded and new roles, respectively, signaling an orderly transition in key corporate governance positions. These changes are expected to maintain the company’s adherence to Hong Kong listing and companies ordinance requirements without operational disruption, providing reassurance to investors and other stakeholders about the stability of its administrative and compliance functions.

The most recent analyst rating on (HK:1228) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

More about CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a biopharmaceutical company listed on the Stock Exchange of Hong Kong, focusing on the development and commercialization of innovative therapies. The company operates under a board comprising executive, non-executive and independent non-executive directors, reflecting a standard governance structure for a listed pharma issuer.

Average Trading Volume: 3,315,095

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.34B

Learn more about 1228 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1